Surgical Endoscopy

, Volume 31, Issue 10, pp 3783–3790 | Cite as

SAGES endoluminal treatments for GERD

  • Jonathan Pearl
  • Eric Pauli
  • Brian Dunkin
  • Dimitrios StefanidisEmail author

Gastroesophageal reflux disease (GERD) is a common problem that affects approximately 30–40% of the adult population with at least 20% of Americans reporting weekly symptoms.1,2 GERD accounts for 8.9 million annual outpatient visits with an estimated annual cost of 24 billion dollars.2 For upper gastrointestinal endoscopy alone, the cost to the health care system is estimated at $12.3 billion annually.3 First-line therapy for GERD includes a combination of lifestyle modifications and medical therapy, with antireflux medications accounting for approximately $7.7 billion in annual US health care costs.4 GERD often requires lifelong treatment and is associated with serious health risks including esophagitis, esophageal stricture, Barrett’s, and adenocarcinoma of the esophagus.

Unfortunately, 25–42% of patients with GERD do not respond to an initial 4- to 8-week treatment with proton pump inhibitors (PPI).5In those who do respond to therapy, the effectiveness of PPI treatment decreases...


Compliance with ethical standards


Dr. Stefanidis reports personal fees from WL Gore and Davol. Dr. Brian Dunkin receives speaking honoraria from Boston Scientific Endoscopy, Ethicon, Gore, Medtronic (formerly Covidien), Olympus, and Pacira. He is a consultant for Boston Scientific Endoscopy and Olympus, and also has ownership interest in SurgWise Consulting, LLC. Dr. Pauli consults for Bard, Boston Scientific, and Cook. Dr. Pearl has nothing to disclose.

Copyright information

© Society of American Gastrointestinal and Endoscopic Surgeons (SAGES) 2017

Authors and Affiliations

  1. 1.University of Maryland School of MedicineBaltimoreUSA
  2. 2.Penn State Hershey Medical CenterHersheyUSA
  3. 3.Houston Methodist HospitalHoustonUSA
  4. 4.Indiana University School of MedicineIndianapolisUSA

Personalised recommendations